AUTOGRAFTING FOR LYMPHOMA

自体移植治疗淋巴瘤

• 批准号: 6395686
• 负责人: SANDRA J. HORNING
• 金额: $ 22.14万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-03-13 至 2001-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6395686
• 关键词: Hodgkin's disease; autologous transplantation; bone marrow transplantation; clinical research; cyclophosphamide; cytokine; dosage; hematopoietic tissue transplantation; human subject; human therapy evaluation; lomustine; lymphokine activated killer cell; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence; nonHodgkin's lymphoma

It is the objective of our studies to improve the results of treatment with high dose therapy and autografting in Hodgkin's disease and the non-Hodgkin's lymphomas. We intend to accomplish this goal through the study of novel preparatory regimens and post-transplant immunotherapy. Complementary pathology studies are planned to better define biologic correlates of the clinical results. The proposed clinical studies build on our previous research in these diseases. A new preparatory regimen (CCNU, VP16, cyclophosphamide) developed at Stanford University will be evaluated in patients with low risk Hodgkin's disease. Multiple cycle high dose therapy has been developed to reduce relapse in high risk Hodgkin's disease patients. We will compare the efficacy and toxicity of high dose sequential chemotherapy with our standard preparatory regimen in a Phase III trial in non-Hodgkin's lymphoma. Correlations will be made with a number of biologic parameters assessed in lymphoma tissues in order to further elucidate factors that may predict the treatment outcome after high dose therapy and autografting. All autografted patients will be studied by sensitive molecular and cytogenetic techniques designed to predict genomic instability and the risk for treatment- related myelodysplasia or acute leukemia. In collaboration with investigators in Project III, we will study the feasibility and toxicity of infusing cytokine-induced killer cells into patients with refractory non-Hodgkin's lymphoma. These CIK cells represent a novel therapeutic which, when used as an adjunct to high dose therapy and autografting, may reduce the major problem of relapse after autografting. The studies in Project II are based on past accomplishments in the research laboratory and the clinic. Analysis of previous experience allows us to define risk groups in Hodgkin's disease and structure preparatory regimens accordingly. We plan a comprehensive approach to the study of non-Hodgkin's lymphoma by characterizing lymphoma tissues, purging lymphoma from the apheresis product, comparing two preparatory regimens, and introducing a novel post-transplant immunotherapy to the clinic. The potential for myelodysplasia or acute leukemia as a late effect of high dose therapy will be studied prospectively in all patients. Project II will serve as a clinical resource for other subprojects.

这是我们研究改善治疗结果的目的 高剂量疗法和霍奇金氏病和自动锻炼 非霍奇金的淋巴瘤。 我们打算通过 新的预备方案和移植后的研究 免疫疗法。 互补的病理研究计划更好 定义临床结果的生物学相关性。 拟议的临床研究以我们先前的研究为基础 疾病。 一种新的预备方案（CCNU，VP16，环磷酰胺） 在斯坦福大学开发的患者将进行评估 低风险霍奇金氏病。 多周期高剂量疗法已经 为了减少高风险霍奇金病患者的复发而发展。 我们将比较高剂量顺序的功效和毒性 在第三阶段的标准预备方案的化学疗法 非霍奇金淋巴瘤中的试验。 相关性将与 在淋巴瘤组织中评估的生物学参数数量 进一步阐明可能预测治疗结果的因素 高剂量疗法和自动疗法后。 所有自体移植患者 将通过敏感的分子和细胞遗传学技术研究 旨在预测基因组不稳定性和治疗风险 - 相关的骨髓增生或急性白血病。 与 第三项目的调查人员，我们将研究可行性和 注入细胞因子诱导的杀伤细胞的毒性 难治性非霍奇金淋巴瘤。 这些CIK细胞代表了新颖 当用作高剂量疗法的辅助和 自动锻炼，可能会减少重新解体的主要问题 自动加法。 第二项项目的研究基于过去的成就 研究实验室和诊所。 对先前经验的分析 允许我们在霍奇金氏病和结构中定义风险群体 相应的准备方案。 我们计划一种全面的方法 通过表征淋巴瘤来研究非霍奇金淋巴瘤 组织，从磨牙产物清除淋巴瘤，比较两个 预备方案，并引入一种新颖的移植物 对诊所的免疫疗法。 骨髓增生或 将研究急性白血病作为高剂量疗法的晚期作用 前瞻性所有患者。 II项目将作为临床 其他子项目的资源。